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Seldom has an article, which merely regurgitates previously widely known information, produced such a wide response in the ophthalmic and medical community as the recent editorial in the BMJ by Doona Delay between exposure to chloramphenicol and occurrence of drug induced aplastic anaemia clouds the relation. 8 Of those blood dyscrasias induced by systemic chloramphenicol, only 22% of cases manifest the dyscrasia while on the drug, with a median delay of 38 days to onset of dyscrasia from discontinuation of chloramphenicol and in 10% of cases the dyscrasia occurs more than 130 days after discontinuation.8 Further confounding variables might be failure to identify earlier exposure to chloramphenicol (especially because of this delayed onset) biasing towards underestimation of associated toxicity, although the latter is almost certainly countered by the high awareness of physicians of chloramphenicol induced aplastic anaemia, possibly leading to over incrimination of chloramphenicol, as opposed to other candidate drugs known to cause idiosyncratic aplastic anaemia such as sulpha based drugs and phenothiazines.7 11 In respect of risk associated with topical therapy, the authors feel that unfounded published statements such as 'Actually there are no data to support the belief that the incidence is any less than after systemic therapy'29 can only serve to confuse and cause panic in the prescribing physician. Considering the very widespread level of prescription of topical chloramphenicol, one would expect more than 23 published 'possibles' in the literature to date if the risk were to equal that of systemic therapy,2' which obviously represents an absolute theoretical maximum for topical therapy. However, it is acknowledged that spontaneous reporting may not necessarily equate with absolute incidence. Doona and Walsh' postulate that the risk of topical chloramphenicol may be similar to that of systemic therapy on the basis that 'topical administration can achieve systemic effects by absorption through the conjunctival membrane or through drainage down the lacrimal duct' citing a letter30which actually discusses the quite distinctly different scenario of subconjunctival administration of chloramphenicol in rabbits. While it is acknowledged that minuscule amounts of drug can theoretically precipitate idiosyncratic reactions, Trope et a122 performed a study in children to determine systemic absorption of topical chloramphenicol concluding that significant absorption directly from the eye into the circulation or via the nasolacrimal system and gastrointestinal tract did not occur, or that the urinary drug levels were lower than that detectable by the analytical technique (working assay limit 1 ,ug/ml). The authors, however, did go on to express concern regarding systemic absorption associated with 'excessively prolonged usage' which was not specifically addressed by their sensitive study. It should be noted that the minimum reported total topical dose of chloramphenicol proposed to be associated with marrow toxicity is 30 mg and the minimum associated duration of exposure is 18 
